A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

ABSTRACT:

Background

Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma.

Methods

A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma treated with eribulin. Eligible patients were between 12 and 50 years of age, had measurable tumor, and met standard organ function requirements. Patients were given eribulin 1.4 mg/m² /dose on days 1 and 8 of each 3-week cycle for up to 24 months if there was no progressive disease. Response

SUBMITTER: Isakoff MS 

PROVIDER: S-EPMC6501793 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature